Last updated: February 20, 2026
Calcitonin-salmon, a synthetic form of salmon calcitonin, is used for the treatment of osteoporosis, hypercalcemia, and other conditions. Multiple suppliers globally manufacture and distribute this peptide, often under brand names like Miacalcin, Fortical, and others.
Major Suppliers and Manufacturers
| Supplier |
Country of Origin |
Regulatory Approvals |
Market Presence |
Production Capacity |
Notes |
| Novartis (Mariusz) |
Switzerland |
EMA, FDA |
Global, extensive |
High, large-scale production |
Primary global supplier for branded formulations |
| Fresenius Kabi |
Germany |
EMA, FDA |
Europe, US, Asia |
Significant, manufacturing scale |
Provides generic calcitonin-salmon formulations |
| Sandoz (Novartis affiliate) |
Switzerland |
EMA, FDA |
US, Europe, emerging markets |
Large-scale, biosimilar production |
Produces biosimilar versions of calcitonin-salmon |
| Bharat Serums and Vaccines |
India |
DCGI (India), FDA (US) |
India, export markets |
Moderate capacity |
Focuses on regional markets, expanding exports |
| BioSante Pharmaceuticals |
US |
FDA |
US, select markets |
Limited, specialty products |
Historically an innovator, acquired by others |
| Modern Oncology & Biosciences |
India |
DCGI |
India |
Growing, regional focus |
Produces generic calcitonin-salmon formulations |
Regulatory and Patent Considerations
- Patent Status: Certain patents for formulation and delivery mechanisms have expired, increasing generic competition.
- Regulatory Approvals: In the U.S., products compliant with FDA standards include Miacalcin (by Novartis) and Fortical (by Teva). In Europe, EMA approvals mirror U.S. approvals for marketed products.
- Biosimilar Market: Since biosimilar versions entered the market, competition has increased, primarily led by Sandoz and Fresenius Kabi.
Supply Chain Dynamics
- Manufacturing Complexity: Calcitonin-salmon is produced via recombinant DNA technology, requiring specialized facilities.
- Global Distribution: Suppliers primarily export to North America, Europe, and Asia. Some regional producers cater exclusively to local markets.
- Pricing Trends: The entry of biosimilars has driven prices downward, impacting margins for original innovators.
Key Market Trends
- Increased Generic Availability: Patent expiration in the 2010s led to market saturation with biosimilars.
- Demand Drivers: Growing osteoporosis prevalence, especially in aging populations, sustains demand.
- Shipping & Storage: Thermally sensitive, requiring cold chain logistics that influence supply chain choices.
Summary
Multiple pharmaceutical companies supply calcitonin-salmon, with regional variations in market dominance. The landscape shifted with biosimilar entries and patent expirations, leading to increased competition and reduced prices. Major players include Novartis, Fresenius Kabi, and Sandoz, with regional producers in India and other emerging markets expanding their footprints.
Key Takeaways
- Several global suppliers produce calcitonin-salmon, with Novartis and Sandoz leading in market share.
- Biosimilar versions have increased competition, impacting pricing.
- Production relies on complex recombinant DNA technology, requiring specialized manufacturing facilities.
- Supply is concentrated in North America, Europe, and Asia, with regional producers serving local markets.
- Patent expirations have enabled generic and biosimilar entry, influencing pricing and market dynamics.
FAQs
1. Who are the main global suppliers of calcitonin-salmon?
Novartis, Sandoz, and Fresenius Kabi are the largest international suppliers, offering branded and biosimilar versions.
2. Are biosimilars available for calcitonin-salmon?
Yes. Biosimilars from Sandoz and others are available in multiple markets, increasing competition.
3. What are the primary markets for calcitonin-salmon?
North America, Europe, and Asia are the principal markets, with regional manufacturers serving local needs.
4. How has patent expiration affected the supply landscape?
Patent expiration has led to increased biosimilar availability, reducing prices and encouraging market entry by generic manufacturers.
5. What production technologies are involved?
Recombinant DNA technology is used to produce calcitonin-salmon, requiring specialized biotech manufacturing facilities.
References
[1] U.S. Food and Drug Administration (FDA). (2023). Calcitonin: Drug Information.
[2] European Medicines Agency (EMA). (2023). Calcitonin-containing medicines overview.
[3] Novartis AG. (2023). Product portfolio details.
[4] Sandoz International GmbH. (2023). Biosimilar calcitonin information.
[5] Bharat Serums and Vaccines. (2023). Company profile and product offerings.
